



RECEIVED

NOV 03 2003

TECH CENTER 1600/2900

PATENT APPLICATION

File No: 97-11C2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : Paul O. Sheppard, Laura J. Jelinek
Serial No. : 10/082,502
Group Art Unit : 1642
Examiner : Nickol, G.B.
Filed : October 19, 2001
For : MAMMALIAN SECRETORY PEPTIDE - 9

CERTIFICATE OF MAILING UNDER 37 C.F.R. 1.8(a)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I hereby certify that the attached correspondence comprising:

1. Information Disclosure Statement (in duplicate)
2. PTO-1449 Form
4. Return Postcard

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on October 23, 2003.



Kim M. Goplen



RECEIVED

NOV 03 2003

PATENT APPLICATION

File No: 97-11C2

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : Paul O. Sheppard, Laura J. Jelinek
Serial No. : 10/082,502
Group Art Unit : 1642
Examiner : Nickol, G.B.
Filed : October 19, 2001
For : MAMMALIAN SECRETORY PEPTIDE - 9
Date Submitted : October 23, 2003

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with the duty imposed by 37 C.F.R. §1.56, and in accordance with 37 C.F.R. §§1.97 *et seq.*, the materials enclosed herewith are brought to the attention of the Examiner as possibly being of interest in connection with the above-identified patent application. Consideration of each of the documents listed on the attached 1449 form(s) is respectfully requested.

The present application is a continuation of U.S. Patent Application No. 09/318,028, filed May 25, 1999; which is a continuation-in-part of U.S. Patent Application No. 09/109,808, filed July 2, 1998, now abandoned.

Pursuant to the provisions of M.P.E.P. §609 and in accordance with 37 C.F.R. §1.98(d), Applicants have not included copies of the documents listed on the 1449 forms that were previously cited by or submitted to the Patent Office in a prior application identified herein.

Pursuant to the provisions of M.P.E.P. §609, Applicants further request that a copy of the 1449 form(s), marked as being considered and initialed by the Examiner, be returned with the next Official Communication.

The Commissioner is hereby authorized to charge the fee under 37 C.F.R. §1.17(p) of \$180.00 to ZymoGenetics, Inc. Deposit Account No. 26-0290. A duplicate of this paper is enclosed.

Respectfully submitted,

Shelby J. Walker
Registration No. 45,192

10/29/2003 LWONDIM1 00000041 260290 10082502

01 FC:1806 2340.00 DA

RECEIVED

NOV 03 2003

Sheet 1 of 6

FORM PTO 1449
(REV 2-32)

**U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE**

File No. 97-11C2

Serial No.
10/082,502

FILE CENTER 1600/2900

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant(s):
Paul O. Sheppard, Laura J. Jelinek

Filing Date:
October 19, 2001

Group: 1642

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	93/03157	02/18/93	PCT		


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Patents, Etc.)

	A2	Rattner, et al., <i>Proc. Natl. Acad. Sci.</i> 94:2859-2863, 1997.
	A3	Expressed Sequence Tag (EST) from Incyte Pharmaceuticals, Inc., 1845530, 9/11/98.
	A4	EST from Incyte Pharmaceuticals, Inc., 185536, 9/11/96.
	A5	EST from Incyte Pharmaceuticals, Inc., 1860787, 9/11/96.
	A6	EST from Incyte Pharmaceuticals, Inc., 1858565, 9/11/96.
	A7	EST from Incyte Pharmaceuticals, Inc., 1835311, 9/11/96.
	A8	EST from Incyte Pharmaceuticals, Inc., 1843520, 9/11/96.
	A9	Published EST 666712, 9/9/96.
	A10	Published EST 657702, 9/3/96.
	A11	Published EST 657743, 9/3/96.
	A12	Published EST 654821, 9/3/96.
	A13	Published EST 651984, 8/26/96.
	A14	Published EST 647379, 8/22/96.
	A15	Published EST 637104, 8/9/96.
	A16	Published EST 1628992, 8/7/96.

Examiner

Date considered

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



RECEIVED

NOV 03 2003

Sheet 2 of 6

FORM PTO 1449
(REV 2-32)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

File No. 97-11C2

Serial No.
10/082,502

TECH CENTER 600/2900

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Applicant(s):
Paul O. Sheppard, Laura J. Jelinek

(Use several sheets if necessary)

Filing Date:
October 19, 2001

Group: 1642

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Patents, Etc.)

	A17	EST from 1555882, 8/7/96.
	A18	EST from Incyte Pharmaceuticals, Inc., 1613409, 8/7/96.
	A19	EST from Incyte Pharmaceuticals, Inc., 1493185, 8/7/96.
	A20	EST from Incyte Pharmaceuticals, Inc., 1495647, 8/7/96.
	A21	EST from Incyte Pharmaceuticals, Inc., 1555854, 8/7/96.
	A22	EST from Incyte Pharmaceuticals, Inc., 1751749, 8/7/96.
	A23	EST from Incyte Pharmaceuticals, Inc., 1646307, 8/7/96.
	A24	EST from Incyte Pharmaceuticals, Inc., 1492851, 8/7/96.
	A25	EST from Incyte Pharmaceuticals, Inc., 1463427, 8/7/96.
	A26	Published EST 619318, 7/25/96.
	A27	Published EST 613030, 8/7/96.
	A28	EST from Incyte Pharmaceuticals, Inc., 1503735, 7/15/96.
	A29	EST from Incyte Pharmaceuticals, Inc., 1477748, 7/15/96.
	A30	EST from Incyte Pharmaceuticals, Inc., 1271650, 6/18/96.

Examiner

Date considered

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



RECEIVED

Sheet 3 of 6

FORM PTO 1449
(REV 2-32)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

NOV 03 2003

File No. 97-11C2

Serial No.
10/082,502

TECH CENTER 1600/2900

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant(s):
Paul O. Sheppard, Laura J. Jelinek

Filing Date:
October 19, 2001

Group: 1642

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Patents, Etc.)

	A31	EST from Incyte Pharmaceuticals, Inc., 1310281, 6/18/96.
	A32	EST from Incyte Pharmaceuticals, Inc., 1379946, 6/18/96.
	A33	Published EST 579223, 6/17/96.
	A34	EST from Incyte Pharmaceuticals, Inc., 1216757, 5/20/96.
	A35	EST from Incyte Pharmaceuticals, Inc., 1284153, 5/20/96.
	A36	EST from Incyte Pharmaceuticals, Inc., 939364, 5/20/96.
	A37	Published EST 516657, 4/26/96.
	A38	Published EST 514884, 4/25/96.
	A39	EST from Incyte Pharmaceuticals, Inc., 716496, 4/23/96.
	A40	EST from Incyte Pharmaceuticals, Inc., 932589, 4/23/96.
	A41	EST from Incyte Pharmaceuticals, Inc., 901376, 4/23/96.
	A42	Published EST 462697, 2/22/96.
	A43	Published EST 448178, 2/9/96.
	A44	EST from Incyte Pharmaceuticals, Inc., 762969, 2/2/96.

Examiner

Date considered

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



RECEIVED

Sheet 4 of 6

FORM PTO 1449
(REV 2-32)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

NOV 03 2003

File No. 97-11C2

Serial No.
10/082,502

TECH CENTER 1600/2900

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Applicant(s):
Paul O. Sheppard, Laura J. Jelinek

Filing Date:
October 19, 2001

Group: 1642

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Patents, Etc.)

	A45	EST from Incyte Pharmaceuticals, Inc., 796152, 2/2/96.
	A46	EST from Incyte Pharmaceuticals, Inc., 724960, 2/2/96.
	A47	EST from Incyte Pharmaceuticals, Inc., 694570, 1/4/96.
	A48	EST from Incyte Pharmaceuticals, Inc., 604074, 12/4/95.
	A49	EST from Incyte Pharmaceuticals, Inc., 605816, 12/4/95.
	A50	EST from Incyte Pharmaceuticals, Inc., 605238, 12/4/95.
	A51	EST from Incyte Pharmaceuticals, Inc., 543893, 11/8/95.
	A52	EST from Incyte Pharmaceuticals, Inc., 551285, 11/8/95.
	A53	EST from Incyte Pharmaceuticals, Inc., 068085, 8/25/95.
	A54	EST from Incyte Pharmaceuticals, Inc., 094969, 8/25/95.
	A55	EST from Incyte Pharmaceuticals, Inc., 358339, 8/25/95.
	A56	Published EST 292894, 7/19/95.
	A57	Published EST 192508, 4/18/95.

Examiner

Date considered

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

NOV 03 2003

Sheet 5 of 6

FORM PTO 1449
(REV 2-32)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

File No. 97-11C2

Serial No.
10/082,502

TECH CENTER 1600/2900

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Applicant(s):

Paul O. Sheppard, Laura J. Jelinek

(Use several sheets if necessary)

Filing Date:
October 19, 2001

Group: 1642

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Patents, Etc.)

A58	Published EST 99745, 2/1/95.
A59	LIN 605816R from Incyte Pharmaceuticals, Inc. 3/25/96.
A60	Hillier et al., The Wash U-Merck EST Project, 1995, Database Genbank, Accession No. R22491, "H sapiens clone IMAGE 130610", XP002083365
A61	Freshney, (Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc., 1983, New York, p4)
A62	Dermer, Bio/Technology 12:320, 1994.
A63	Wilson et al., Genbank Sequence Database (Medline No. 94150718), National Center for Biotechnology Information, National Library of Medicine, Bethesda, Maryland, publicly available November, 1994.
A64	Jaspers et al., Genbank Sequence Database (Accession W88469), National Center for Biotechnology Information, National Library of Medicine, Bethesda, Maryland, publicly available January 14, 1999.

Examiner

Date considered

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

NOV 03 2003

Sheet 6 of 6

FORM PTO 1449
(REV 2-32)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

File No. 97-11C2

Serial No.
10/082,502

TECH CENTER 600/2900

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Applicant(s):

Paul O. Sheppard, Laura J. Jelinek

(Use several sheets if necessary)

Filing Date:
October 19, 2001

Group: 1642

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Patents, Etc.)

A65		Greenspan, "Defining epitopes: It's not as easy as it seems," <u>Nature Biotechnology</u> 17:936-937, 1999.
A66		Bowie et al., "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions," <u>Science</u> 247:1306-1310, 1990.
A67		Alberts et al., <u>Molecular Biology of the Cell</u> , 3 rd edition, page 465, 1994.

Examiner

Date considered

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.